MOZOBIL
Live / Registered — Registered — Section 8 accepted (as of 20 Feb 2025)
What this means for you
Registered since 19 Jun 2018. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87682083
- Registration number
- 5497375
- Mark type
- Stylized text
- Filed
- 13 Nov 2017
- Published for opposition
- 03 Apr 2018
- Registered
- 19 Jun 2018
- Attorney of record
- Karen Lim
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and medicinal preparations for the treatment of cancer, cell transplants and cell transplant rejection, organ transplants and organ transplant rejection, angiogenesis, bacterial infection, peripheral blood stem cell mobilization, lymphoma, tissue regeneration, tissue repair, leukemia, drug-induced anemia, retrovirus, hematopoietic deficit resulting from chemotherapy or radiation therapy, elevation of white blood cells
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 20 Feb 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 20 Feb 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 19 Feb 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 31 May 2024 — TEAS SECTION 8 RECEIVED
- 19 Jun 2023 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 08 Jan 2020 — REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
- 10 Dec 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Apr 2019 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 12 Apr 2019 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 19 Jun 2018 — REGISTERED-PRINCIPAL REGISTER
- 03 Apr 2018 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Apr 2018 — PUBLISHED FOR OPPOSITION
- 14 Mar 2018 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Feb 2018 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Feb 2018 — ASSIGNED TO EXAMINER